Company Name: Haleon Pakistan Limited
Ticker: HALEON
Reporting period: quarter and half year ended June 30, 2026. The condensed interim financial statements are company-level, unaudited accounts. KPMG’s limited-scope review covers the cumulative six-month figures; the standalone three-month Q2 figures for June 2026 and June 2025 were not reviewed. Official H1 2026 report. Official PSX result announcement.
Verdict
Haleon Pakistan’s H1 2026 headline is stronger than its sales trend: net sales fell 9.1%, yet gross profit rose 8.2% and profit after tax increased 7.75%. Q2 tells the same story more sharply—sales fell 13.2%, gross profit rose 7.0% and net profit increased 3.3%. The margin improvement is real in the reported accounts, but it is not cleanly repeatable: the half-year notes disclose a PKR640.31 million favorable customs-related adjustment inside cost of sales and PKR526.43 million of restructuring provisions across cost of sales, selling and administrative expenses. Meanwhile, a PKR3.56 billion inventory build pushed operating cash flow slightly negative. The result therefore combines genuine cost-management resilience with important non-recurring accounting effects and a meaningful working-capital drag. Official H1 2026 statements and notes.
Results at a glance
- Q2 net sales were PKR10.072 billion versus PKR11.598 billion, down 13.2%. Gross profit increased 7.0% to PKR5.003 billion, lifting gross margin to 49.7% from 40.3%, a gain of about 9.4 percentage points. Official Q2/H1 statement.
- Q2 profit before income tax declined about 3.0% to PKR2.668 billion, but profit after tax rose 3.3% to PKR1.676 billion. EPS increased to PKR14.32 from PKR13.87. Net margin improved to 16.6% from 14.0%. Official Q2/H1 statement.
- For H1, net sales fell 9.1% to PKR19.666 billion, gross profit rose 8.2% to PKR8.766 billion, profit before income tax rose 3.4% to PKR5.066 billion and profit after tax rose 7.75% to PKR3.201 billion. H1 EPS was PKR27.35 versus PKR25.38. Official H1 statement.
- The board declared an interim cash dividend of PKR10.00 per share, or 100%, with the August 27 result. Official PSX result announcement.
- Cash conversion weakened materially: net cash used in operating activities was PKR73.9 million versus PKR2.293 billion generated a year earlier, primarily because stock-in-trade absorbed PKR3.565 billion of cash. Official H1 cash-flow statement.
AlphaGen model readings
Alpha QoQ Score: 77.21
TTM Performance Score: 93.96
3Y Business Perf Score: 98.94
Sector Leadership Score: 55.4557
These four readings are AlphaGen model outputs, not company-reported figures. They are shown separately from the public financial statements and do not constitute investment advice.
What improved
The clearest improvement is gross profitability. H1 gross margin expanded to 44.6% from 37.5%, while Q2 gross margin reached 49.7% from 40.3%. Cost of sales fell 19.4% in H1 even though revenue fell 9.1%. That means the direct cost base moved much more favorably than the top line. Management attributes the broader result to productivity and cost-management measures, but the financial notes also show that part of the improvement came from a specific customs-related accrual adjustment, so the full reported margin should not be treated as a clean new run-rate. Official H1 report and note 11.
The tax line also helped net earnings. Q2 tax expense fell to PKR991 million from PKR1.126 billion even though current tax expense increased; a PKR211 million deferred-tax credit replaced a PKR48 million deferred-tax expense in the comparable quarter. That is why Q2 profit after tax rose even as pre-tax profit declined. Deferred-tax movements can reverse, so this support is less durable than operating margin improvement. Official taxation note.
Financial charges remained small at PKR27.6 million for H1, down from PKR32.4 million. The balance sheet shows no conventional long- or short-term financing; the principal financing liability disclosed is lease-related. That leaves Haleon with little direct interest-bearing leverage pressure compared with many industrial businesses. Official H1 notes and Shariah-compliance disclosure.
What weakened / needs attention
The top line is the main weakness. Management said household budgets remained under pressure and consumers prioritized essentials, while discretionary and non-immediate categories—including consumer healthcare—were constrained. H1 OTC sales declined 8.49% year on year and FMCG sales declined 3.09%. Pakistan’s June 2026 CPI was still 11.07% above June 2025, which is consistent with management’s description of persistent cost-of-living pressure, although inflation alone does not prove the company-specific sales decline. Haleon directors’ report. PBS June 2026 CPI.
The sales decline also worsened as the half progressed. By subtraction, Q1 2026 revenue was about PKR9.594 billion versus PKR10.030 billion a year earlier, a decline of roughly 4.3%. Q2 then fell 13.2%. The filing does not provide a quarter-specific bridge between volume, pricing and mix, so the safe conclusion is that demand/top-line pressure intensified in Q2 without assigning an unsupported cause. Derived from the official H1 and Q2 revenue figures.
Operating expenses moved the wrong way relative to sales. Selling, marketing and distribution expense rose 12.2% to PKR3.136 billion, administrative expense rose 18.5% to PKR449 million and other expenses rose 5.0% to PKR438 million. Management says the ratio of total expenses to net sales increased from 16.76% to 20.60%, reflecting higher operating and input costs. This absorbed a large portion of the gross-profit improvement. Official H1 report.
Other income fell 20.0% to PKR356 million. Management attributes the decline mainly to lower interest rates and reduced returns on cash investments. The June accounts show savings-account mark-up rates of 5.08%–8.75%, below the 7.00%–9.50% range disclosed at December 2025, while the SBP policy rate stood at 11.50% after the June 15 monetary-policy decision. Lower treasury and deposit yields are therefore an earnings headwind for a company carrying substantial liquid funds. Haleon financial notes. SBP monetary-policy record.
Recurring versus exceptional earnings drivers
The most important disclosed non-recurring benefit is a PKR640.31 million adjustment to accrued liabilities inside cost of sales after the Supreme Court dismissed a customs petition concerning Haleon’s entitlement to concessional duty rates on specified imports. Because the decision was in Haleon’s favor, the adjustment reduced reported cost of sales and increased gross profit. The note is disclosed for the half year, not allocated to an individual quarter, so it should not be mechanically assigned to Q2. Official note 11.1.
The main exceptional costs move in the opposite direction. Haleon recorded restructuring provisions of PKR4.30 million in cost of sales, PKR489.18 million in selling and marketing, and PKR32.95 million in administrative expenses—PKR526.43 million in total. These charges are not ordinary product-selling costs, but the filing does not say they are finished; further restructuring costs could arise in later periods. Official expense notes.
A simple analytical normalization shows why both sides matter. Mechanically removing the PKR640.31 million customs benefit and adding back the PKR526.43 million restructuring provisions would put H1 profit before income tax at roughly PKR4.95 billion, only about 1% above the prior-year PKR4.90 billion. This is not a company-reported adjusted profit measure and it ignores any tax effect; it is only a bridge to show that the two large disclosed items mostly offset each other at the pre-tax level. Calculated from the official H1 statements and notes.
The customs adjustment also changes how the gross-margin headline should be read. On a purely illustrative basis, removing PKR640.31 million from H1 gross profit would leave about PKR8.13 billion—roughly flat year on year—while the adjusted gross margin would still be around 41.3% versus 37.5%. That suggests there was underlying margin improvement beyond the one-off, but not as much as the reported 44.6% margin implies. Analytical bridge using official figures.
Cash flow and balance sheet
Profit did not convert into cash during the half. Cash generated from operations before tax and other payments fell to PKR2.489 billion from PKR5.011 billion, even though profit before working-capital changes rose slightly to PKR5.285 billion. The difference was working capital: stock-in-trade absorbed PKR3.565 billion, compared with PKR2.581 billion a year earlier, while the increase in payables provided only PKR576 million of cash versus more than PKR2.19 billion in H1 2025. Official cash-flow note.
Inventory reached PKR11.175 billion at June 30, up 45.2% from December. Raw and packing materials were PKR8.474 billion, including PKR3.475 billion in transit, while finished goods were PKR2.914 billion. The filing does not attribute the build to weak sell-through, supply buffering or a deliberate procurement decision, so it would be speculative to choose one explanation. What is clear is that inventory became the largest current asset and the main cash-conversion constraint. Official inventory note.
Liquidity remains substantial despite the cash outflow. Cash and cash equivalents were PKR6.450 billion versus PKR7.159 billion at December, combining bank balances and qualifying short-term investments. Current assets were PKR20.855 billion against current liabilities of PKR13.485 billion, a current ratio of about 1.55x. Excluding inventory, however, liquid current-asset coverage weakened because so much working capital shifted into stock. Official statement of financial position and cash-equivalent note.
Investment in the operating base also accelerated. Cash paid for property, plant and equipment was PKR733 million versus PKR468 million a year earlier, and outstanding capital-expenditure commitments rose to PKR2.858 billion from PKR2.156 billion at December. The interim filing does not provide enough project-level detail to assign those commitments to specific capacity or efficiency programs, but the higher commitment level is material for future cash use. Official cash flow and commitments note.
Operating, regulatory and peer context
Regulation is operationally important because Haleon discloses that transfers of certain OTC marketing authorizations and permissions with DRAP remain pending. Until those transfers are completed, GlaxoSmithKline Pakistan procures, manufactures and manages related inventory and receivables on Haleon’s behalf for a service fee. DRAP also maintains a separate framework for health and OTC products, including a revised policy for vitamin and mineral formulations. Haleon’s directors specifically identify regulatory clarity for nutraceutical and wellness products as important for longer-term industry investment. Haleon note 1.2 and directors’ report. DRAP vitamin/mineral policy.
A broad PSX peer check suggests Haleon’s top-line decline was not universal across the listed healthcare space: Abbott Pakistan’s displayed Q2 2026 sales rose about 6.6% year on year while its profit after tax rose about 13.2%. Abbott has a materially different mix—pharmaceuticals, nutrition, diagnostics and consumer products—so this is not a like-for-like benchmark. It simply argues against treating Haleon’s sales decline as an automatic sector-wide outcome. Abbott Pakistan PSX financial display. Haleon PSX financial display.
Geographically, Haleon remains overwhelmingly domestic. Pakistan generated PKR19.654 billion of H1 revenue; the Philippines contributed PKR11.66 million and Kenya contributed none in the period. That concentration means Pakistan household demand, local regulation, availability and execution matter far more to near-term results than export-market diversification. Official revenue-disaggregation note.
What to monitor next
- Sales stabilization: Q2 revenue contraction was materially worse than the implied Q1 decline. The next quarter needs to show whether consumer-health demand and product availability can arrest that deterioration.
- Gross-margin durability: separate normal cost/mix improvement from the PKR640 million customs accrual adjustment. The next clean quarter will be more informative than the H1 headline. Official customs note.
- Restructuring: H1 provisions totaled roughly PKR526 million. Watch whether further charges appear and whether operating expenses begin to grow more slowly than sales. Official restructuring notes.
- Inventory and cash conversion: stock rose 45% from December and consumed PKR3.56 billion of cash. A reversal of that build would materially improve cash generation; another increase would tighten quality of earnings further. Official balance sheet and cash-flow note.
- Regulatory transfers and supply continuity: the pending OTC authorization/permission transfers and the continuing GSK Pakistan operating arrangement remain important dependencies until resolved. Official company-operations note.
- Tax quality: Q2 net profit benefited from a sizeable deferred-tax credit. Future quarters should be judged on pre-tax operating progress as well as reported net income.
Bottom line
Haleon Pakistan protected earnings remarkably well against a softer top line in H1 2026. Reported margins widened, leverage remained minimal and the company still held more than PKR6.4 billion of cash equivalents. But the quality of that improvement is mixed: a favorable customs adjustment reduced cost of sales, restructuring provisions weighed on expenses, deferred tax supported Q2 net profit, and inventory absorbed enough cash to turn operating cash flow slightly negative. Official H1 statements and notes.
The next result cycle is therefore less about whether accounting profit can remain positive and more about whether three things converge: sales stabilize, margins remain strong without the customs benefit, and inventory converts back into cash. If those occur together, H1 will look like a transition toward structurally better economics. If not, the quarter will have been a profitable but unusually assisted period.
Sources
- Haleon Pakistan Limited — official PSX second quarterly / half-year report for the six months ended June 30, 2026. Open source.
- Haleon Pakistan Limited — official PSX financial-results announcement for the half year ended June 30, 2026, including the interim dividend. Open source.
- Pakistan Stock Exchange — Haleon Pakistan company profile, announcement feed and financial history. Open source.
- Pakistan Bureau of Statistics — CPI inflation press release for June 2026. Open source.
- State Bank of Pakistan — monetary-policy statements and June 15, 2026 policy-rate record. Open source.
- Drug Regulatory Authority of Pakistan — revised policy for registration/enlistment of vitamin and mineral formulations. Open source.
- Pakistan Stock Exchange — Abbott Laboratories (Pakistan) Limited financial display for broad peer context. Open source.